EPS for Oxford Immunotec Global PLC (OXFD) Expected At $-0.36

February 18, 2018 - By Dolores Ford

 EPS for Oxford Immunotec Global PLC (OXFD) Expected At $ 0.36
Investors sentiment decreased to 1.13 in 2017 Q3. Its down 0.14, from 1.27 in 2017Q2. It is negative, as 3 investors sold Oxford Immunotec Global PLC shares while 27 reduced holdings. 12 funds opened positions while 22 raised stakes. 22.51 million shares or 13.08% more from 19.91 million shares in 2017Q2 were reported.
Pennsylvania-based Vanguard Group Inc has invested 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Fosun Int Limited invested in 237,783 shares. New York-based Perceptive Advisors Ltd Llc has invested 0.3% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Penn Cap invested in 0.19% or 158,603 shares. Bank & Trust Of Montreal Can invested in 9,492 shares. Kornitzer Capital Mgmt Ks reported 0.02% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Citigroup Inc, a New York-based fund reported 70 shares. Deerfield holds 945,710 shares. Wells Fargo & Company Mn stated it has 38,720 shares or 0% of all its holdings. Northern Tru reported 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Ameritas Investment Ptnrs Inc reported 1,917 shares. Grp owns 15,167 shares for 0% of their portfolio. Alyeska Investment Gp Limited Partnership reported 1.36 million shares. Millennium Management Llc reported 37,520 shares or 0% of all its holdings. Barclays Public Ltd Liability Company accumulated 524 shares.

Since August 15, 2017, it had 0 insider buys, and 2 selling transactions for $970,393 activity. Edwardson Peter also sold $157,171 worth of Oxford Immunotec Global PLC (NASDAQ:OXFD) on Tuesday, August 15. $47,460 worth of Oxford Immunotec Global PLC (NASDAQ:OXFD) was sold by SANDBERG RICHARD A on Friday, September 1.

Analysts expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to report $-0.36 EPS on February, 27.They anticipate $0.14 EPS change or 63.64 % from last quarter’s $-0.22 EPS. After having $-0.24 EPS previously, Oxford Immunotec Global PLC’s analysts see 50.00 % EPS growth. The stock increased 0.42% or $0.05 during the last trading session, reaching $11.91. About 86,984 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 54.26% since February 18, 2017 and is uptrending. It has outperformed by 37.56% the S&P500.

Oxford Immunotec Global PLC (NASDAQ:OXFD) Ratings Coverage

Among 4 analysts covering Oxford Immunotec (NASDAQ:OXFD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oxford Immunotec had 10 analyst reports since July 19, 2017 according to SRatingsIntel. The firm has “Buy” rating by Robert W. Baird given on Thursday, October 19. On Wednesday, July 19 the stock rating was maintained by Cowen & Co with “Buy”. Cowen & Co maintained the stock with “Buy” rating in Wednesday, September 27 report. Piper Jaffray maintained Oxford Immunotec Global PLC (NASDAQ:OXFD) rating on Monday, January 8. Piper Jaffray has “Buy” rating and $15.0 target. The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) has “Buy” rating given on Monday, January 22 by Cowen & Co. The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) has “Buy” rating given on Thursday, September 28 by BTIG Research. Cowen & Co maintained the shares of OXFD in report on Tuesday, October 31 with “Buy” rating. The firm has “Buy” rating given on Wednesday, August 16 by Cowen & Co. The rating was maintained by Robert W. Baird with “Buy” on Tuesday, October 31.

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for the management of immune-regulated conditions. The company has market cap of $305.55 million. The Company’s development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. It currently has negative earnings. The firm develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

More notable recent Oxford Immunotec Global PLC (NASDAQ:OXFD) news were published by: Seekingalpha.com which released: “Oxford Immunotec Global’s (OXFD) CEO Peter Wrighton-Smith on Q3 2017 Results …” on October 31, 2017, also Globenewswire.com with their article: “Oxford Immunotec Names Karen Koski Head of Strategy and Investor Relations” published on June 05, 2017, Seekingalpha.com published: “Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q1 2017 Results …” on May 02, 2017. More interesting news about Oxford Immunotec Global PLC (NASDAQ:OXFD) were released by: Seekingalpha.com and their article: “Oxford Immunotec, Qiagen settle patent litigation” published on December 15, 2017 as well as Metrowestdailynews.com‘s news article titled: “Oxford Immunotec Global PLC announces acquisition of Imugen Inc” with publication date: June 26, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: